Key Events This Week
23 Feb: Stock hits 52-week and all-time low at Rs.55.85
24-26 Feb: Price stabilises near Rs.59.50 with muted volume
27 Feb: Stock falls sharply to Rs.56.97, marking fresh 52-week low
23 February 2026: Stock Hits 52-Week and All-Time Low Amid Weak Financials
On Monday, 23 February, Valiant Laboratories Ltd’s share price plunged to a fresh 52-week and all-time low of Rs.55.85. This marked a significant milestone in the stock’s prolonged decline, closing down 2.74% on the day despite the Sensex gaining 0.39%. The stock’s underperformance was stark, lagging its sector by 5.76%, and trading below all key moving averages, signalling sustained bearish momentum.
The company’s financial metrics remain under pressure, with the December 2025 quarter reporting a net loss after tax (PAT) of Rs. -7.06 crores, a steep 657.0% decline compared to the previous four-quarter average. Earnings before depreciation, interest, and taxes (PBDIT) were also negative at Rs. -0.89 crores, with an operating profit margin of -1.70%. Return on equity (ROE) averaged a low 0.80%, reflecting limited profitability. The EBIT to interest coverage ratio of -3.50 further highlights the company’s weak debt servicing capacity.
24-26 February 2026: Price Stabilises Amid Muted Trading
Following the sharp decline, the stock price stabilised around Rs.59.50 on 24 and 25 February, with negligible day changes and subdued volumes of 840 shares. The Sensex, meanwhile, experienced a decline of 0.78% on 24 February but rebounded 0.41% on 25 February. On 26 February, the stock gained 0.82% to Rs.59.99 on low volume of 200 shares, slightly outperforming the Sensex’s 0.19% gain. Despite this brief respite, the stock remained below all key moving averages, indicating persistent downward pressure.
Our current Stock of the Month is out! This Large Cap from Automobiles - Passenger Cars emerged as the single best opportunity from our elite universe. Get the details now!
- - Current monthly selection
- - Single best opportunity
- - Elite universe pick
27 February 2026: Sharp Decline to Fresh 52-Week Low on Heavy Volume
The week ended with a sharp sell-off on 27 February, as Valiant Laboratories Ltd’s stock fell 5.03% intraday to an intraday low of Rs.56.50 before closing at Rs.56.97, down 5.05% on the day. This marked a fresh 52-week low close, just 1.95% above the all-time low set earlier in the week. The volume surged to 4,438 shares, indicating increased selling pressure. The stock underperformed the Sensex, which declined 1.16% on the same day.
This decline coincided with the company’s downgrade to a Mojo Grade of Strong Sell with a Mojo Score of 17.0 by MarketsMOJO, reflecting deteriorating fundamentals. The stock’s price-to-book value remains at 1.0, which is expensive relative to its low ROE of 1.6%. The company’s financial challenges, including a 4.8% profit decline over the past year and weak debt servicing metrics, continue to weigh on investor sentiment.
Why settle for Valiant Laboratories Ltd? SwitchER evaluates this micro-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Weekly Price Performance: Valiant Laboratories Ltd vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-02-23 | Rs.59.70 | +1.07% | 36,817.86 | +0.39% |
| 2026-02-24 | Rs.59.50 | -0.34% | 36,530.09 | -0.78% |
| 2026-02-25 | Rs.59.50 | +0.00% | 36,679.75 | +0.41% |
| 2026-02-26 | Rs.59.99 | +0.82% | 36,748.49 | +0.19% |
| 2026-02-27 | Rs.56.97 | -5.03% | 36,322.56 | -1.16% |
Key Takeaways from the Week
Persistent Downtrend: The stock’s fall to fresh 52-week and all-time lows underscores ongoing financial and operational difficulties, with no signs of reversal as it remains below all key moving averages.
Financial Weakness: Negative quarterly PAT of Rs. -7.06 crores and PBDIT of Rs. -0.89 crores, combined with a low ROE averaging 0.80%, highlight the company’s profitability challenges. The poor EBIT to interest coverage ratio of -3.50 signals difficulty in servicing debt obligations.
Underperformance vs Market: The stock’s 3.56% weekly decline significantly outpaced the Sensex’s 0.96% fall, reflecting company-specific headwinds rather than broader market weakness alone.
Conclusion
Valiant Laboratories Ltd’s share price performance over the week ending 27 February 2026 reflects a continuation of its prolonged downtrend amid deteriorating financial fundamentals. The stock’s fresh 52-week lows, weak profitability metrics, and poor debt servicing capacity have contributed to its downgrade to a Strong Sell rating by MarketsMOJO. Despite brief stabilisation midweek, the sharp sell-off on Friday highlights persistent investor concerns. Relative to the broader market and sector, Valiant Laboratories Ltd remains a laggard, underscoring the challenges it faces in regaining momentum within the Pharmaceuticals & Biotechnology sector.
Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →
